Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/106037
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Latham, S. | - |
dc.contributor.author | Bartley, P. | - |
dc.contributor.author | Budgen, B. | - |
dc.contributor.author | Ross, D. | - |
dc.contributor.author | Hughes, E. | - |
dc.contributor.author | Branford, S. | - |
dc.contributor.author | White, D. | - |
dc.contributor.author | Hughes, T. | - |
dc.contributor.author | Morley, A. | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Journal of Clinical Pathology, 2016; 69(9):817-821 | - |
dc.identifier.issn | 0021-9746 | - |
dc.identifier.issn | 1472-4146 | - |
dc.identifier.uri | http://hdl.handle.net/2440/106037 | - |
dc.description.abstract | RT-qPCR is used to quantify minimal residual disease (MRD) in chronic myeloid leukaemia (CML) in order to make decisions on treatment, but its results depend on the level of BCR-ABL1 expression as well as leukaemic cell number. The aims of the study were to quantify inter-individual differences in expression level, to determine the relationship between expression level and response to treatment, and to investigate the effect of expression level on interpretation of the RT-qPCR result.BCR-ABL1 expression was studied in 248 samples from 65 patients with CML by determining the difference between MRD quantified by RT-qPCR and DNA-qPCR. The results were analysed statistically and by simple indicative modelling.Inter-individual levels of expression approximated a normal distribution with an SD of 0.36 log. Expression at diagnosis correlated with expression during treatment. Response to treatment, as measured by the number of leukaemic cells after 3, 6 or 12 months of treatment, was not related to the level of expression. Indicative modelling suggested that interpretation of RT-qPCR results in relation to treatment guidelines could be affected by variation in expression when MRD was around 10% at 3 months and by both expression variation and Poisson variation when MRD was around or below the limit of detection of RT-qPCR.Variation between individuals in expression of BCR-ABL1 can materially affect interpretation of the RT-qPCR when this test is used to make decisions on treatment. | - |
dc.description.statementofresponsibility | Susan Latham, Paul A Bartley, Bradley Budgen, David M Ross, Elizabeth Hughes, Susan Branford, Deborah White, Timothy P Hughes, Alexander A Morley | - |
dc.language.iso | en | - |
dc.publisher | BMJ Publishing Group | - |
dc.rights | © 2016, BMJ Publishing Group Ltd and the Association of Clinical Pathologists | - |
dc.source.uri | http://dx.doi.org/10.1136/jclinpath-2015-203538 | - |
dc.subject | Neoplasm, Residual | - |
dc.title | BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1136/jclinpath-2015-203538 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ross, D. [0000-0001-7171-2935] | - |
dc.identifier.orcid | Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981] | - |
dc.identifier.orcid | White, D. [0000-0003-4844-333X] | - |
dc.identifier.orcid | Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.